RE:RE:CNS: Dicerna ’s GalXC-Plus ™ RNAi TechnologyI don't post often on BTI but since I'm here.... to me this PR from Dicerna suggests opportunity for BTI since the treatment discussed was administered via intrathecal or intracisternal injection. Delivery of drug combnedi with xB3 obviously eliminates the need for these invasive types of injections.